Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer
Rattachement africain : cn, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background This study assessed the efficacy and safety of radiotherapy (RT) plus immunochemotherapy in oligometastatic esophageal cancer (OMEC).Methods A single-center retrospective study of OMEC patients who received immunochemotherapy from Jan 2019 to Jan 2022.Results About 226 patients were included, which consisted of 108 cases in the RT plus immunochemotherapy group (iCRT), and 118 cases in the immunochemotherapy group (iCT). With a median follow-up of 22.2 months, the median progression-free survival (PFS) was 13.0 months for the iCRT group and 7.7 months for the iCT group (p < 0.001, HR = 0.520, 95%CI, 0.388–0.696). The median overall survival (OS) was 27.5 months for the iCRT group and 21.7 months for the iCT group (p = 0.026, HR = 0.670, 95%CI, 0.468–0.958). The iCRT group was associated with a higher risk of ≥grade 3 myelosuppression. No grade 5 treatment-related adverse events were observed. Univariate and multivariate analysis showed that a history of alcohol consumption, more metastatic lesions, and second-line and above treatment had inferior PFS in OMEC patients. A lower Karnofsky performance status score, more metastatic lesions, and second-line and above treatment were found to have inferior OS.Conclusion Compared to immunochemotherapy alone, RT plus immunochemotherapy showed survival benefits with manageable safety for OMEC patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer
- Date Crossref
- 16/12/2025
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Shandong Tumor Hospital pays non établi dans la noticeÉtablissement de santé
-
Shandong First Medical University Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Academy of Medical Sciences pays non établi dans la noticeOrganisation à but non lucratif
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Research Unit of Radiation Oncology pays non établi dans la noticeStructure de recherche
Shandong Tumor Hospital, Department of Radiation Oncology — Shandong First Medical University et Academy of Medical Sciences, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.